Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

David Burks

Urology Jackson, MI Medical Doctor

NPI 1033279906 CMS profile 228448

744 W Michigan Ave Ste 300, Jackson, MI 49201

Open in the dashboard

General payments

$21,509

35 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, David Burks of Jackson, MI is reported in the CMS Open Payments database as having received $21,509 across 35 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $163 3
2021 General $2 1
2020 General $161 3
2019 General $21,183 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Burks
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to David Burks were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year David Burks Urology median Middle half National median
2019 $21,183 $480 $147–$1,201 $163
2020 $161 $246 $87–$645 $114
2021 $2 $358 $111–$1,000 $132
2022 $0 $476 $143–$1,263 $149
2023 $0 $560 $168–$1,461 $160
2024 $163 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Astellas Pharma US Inc $21,009 22 payments
  2. Coloplast Corp $139 3 payments
  3. Boston Scientific Corporation $113 2 payments
  4. Medtronic USA, Inc. $111 1 payment
  5. Ambu Inc. $67 3 payments
  6. TOLMAR Pharmaceuticals, Inc. $24 1 payment
  7. Ferring Pharmaceuticals Inc. $16 1 payment
  8. Pfizer Inc. $15 1 payment
  9. Allergan Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,663 7 payments
  2. Food and Beverage $957 21 payments
  3. Travel and Lodging $889 7 payments
Products named General payments · program years 2019–2024
  1. MYRBETRIQ $20,997 21 payments
  2. INTERSTIM $111 1 payment
  3. AMS 800 Artificial Urinary Sphincter $98 1 payment
  4. RESTORELLE $90 1 payment
  5. ALTIS $49 2 payments
  6. XTANDI $27 2 payments
  7. VESICARE $25 2 payments
  8. ELIGARD $24 1 payment
  9. NOCDURNA $16 1 payment
  10. GREENLIGHT $15 1 payment
  11. Other $28 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,112

Median for Urology: 1,053

Drug cost

$98,433

Median for Urology: $101,464

Branded share of claims

21.6%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 106 $75,602
Solifenacin Succinate Generic 253 $11,016
Tamsulosin Hcl Generic 225 $4,431
Oxybutynin Chloride Er Oxybutynin Chloride Brand 64 $1,549
Finasteride Generic 56 $1,258
Tolterodine Tartrate Er Tolterodine Tartrate Brand 27 $1,034
Trospium Chloride Generic 17 $1,033
Bicalutamide Generic 21 $683
Ciprofloxacin Hcl Generic 126 $471
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 17 $362

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$85,320

Medicare's payments for the services billed

Medicare patients

486

Average age 75

Services billed

998

199 women, 287 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 39%
Diabetes 37%
Chronic kidney disease 36%
Heart failure 29%
Depression 29%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

35 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record